Prolonged survival of heart allografts transduced with AAV-CTLA4Ig

Microsurgery. 2003;23(5):489-93. doi: 10.1002/micr.10181.

Abstract

Organ grafts transduced with gene-encoding immunosuppressive molecules are a less toxic approach to preventing graft rejection. Adenovirus vectors have been widely tested with unsatisfactory results, while adeno-associated virus (AAV) is smaller and elicits a low host humoral response. We constructed an AAV vector containing the mouse CTLA4Ig gene. B10 (H2(b)) cardiac grafts were transduced with AAV-CTLA4Ig by coronary infusion. AAV-LacZ vectors were used as reporters and controls, and the expression of beta-gal was determined by X-gal staining. Thirty percent to 40% of myocytes displayed strongly positive X-gal staining after infusion with AAV-LacZ. Additional infusion with vascular dilator reagents did not improve the transduction rate. Survival of B10 heart allografts transduced with AAV-CTLA4-Ig was significantly prolonged in C3H (H2(k)) recipients. These data demonstrate that AAV vectors can efficiently be transduced into the mouse myocardium by coronary infusion. Graft transduction with AAV-CTLA4Ig may be a novel approach to preventing allograft rejection.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antigens, CD
  • Antigens, Differentiation / pharmacology*
  • CTLA-4 Antigen
  • Dependovirus / genetics
  • Genetic Vectors / pharmacology*
  • Graft Rejection / prevention & control
  • Graft Survival / drug effects*
  • Graft Survival / genetics
  • Heart Transplantation / immunology*
  • Heart Transplantation / physiology
  • Immunosuppressive Agents / pharmacology*
  • Male
  • Mice
  • Mice, Inbred C3H
  • Mice, Inbred C57BL
  • Models, Animal
  • Recombinant Fusion Proteins / pharmacology*
  • Transduction, Genetic / methods

Substances

  • Antigens, CD
  • Antigens, Differentiation
  • CTLA-4 Antigen
  • Ctla4 protein, mouse
  • Immunosuppressive Agents
  • Recombinant Fusion Proteins